Iloprost Teva (Iloprost)

Iloprost acts as a selective agonist of the prostacyclin (IP) receptor on vascular smooth‑muscle cells. Activation increases cyclic AMP, causing potent vasodilation of pulmonary arteries and inhibition of platelet aggregation, which together reduce pulmonary arterial pressure.

The dosing regimen for Iloprost is individualized. A qualified prescriber determines the appropriate dose, infusion rate, and duration based on the patient’s clinical status, response, and tolerance. Specific dosing details should be obtained from the treating physician.

Safety data for Iloprost during pregnancy and lactation are limited. The drug should be used only if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Iloprost Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will provide pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Iloprost is a prostacyclin analog similar to epoprostenol and treprostinil but differs in pharmacokinetics and administration. Compared with epoprostenol, Iloprost has a longer half‑life and can be given subcutaneously, offering more flexible dosing. Treprostinil also provides oral and inhaled forms, whereas Iloprost is available only as an injectable solution.

Iloprost solution for injection must be stored refrigerated at 2‑8 °C. Protect it from light, do not freeze, and avoid shaking the vial. Keep the product in its original packaging until use to maintain stability and sterility.

Iloprost is administered by intravenous or subcutaneous injection, typically as a continuous infusion using an infusion pump. The exact route, rate, and duration are prescribed by the treating physician and should be performed by trained healthcare professionals in an appropriate clinical setting.

Serious adverse events include severe hypotension, pulmonary edema, significant bleeding, thrombocytopenia, and chest pain. Patients should be monitored closely for abrupt drops in blood pressure, respiratory distress, or signs of bleeding, and any such events require immediate medical attention.

Iloprost is contraindicated in patients with known hypersensitivity to iloprost or any component of the formulation. It should also be avoided in individuals with uncontrolled severe hypotension, active bleeding disorders, or recent major surgery unless the prescriber determines that benefits outweigh the risks.